Comparing Lymphocyte Radiosensitivity of Prostate Cancer Patients with Healthy Donors Using Micronuclei and Chemical Premature Chromosome Condensation Tests.
Cytogenetic Analysis
Dose-Response Relationship
Micronuclei Tests
Prostatic Neoplasms
Radiation Tolerance
Journal
Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
29
09
2016
accepted:
24
10
2016
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Cytogenetic tests are usually used for diagnosing predisposed individuals to cancer by determining their lymphocyte radiosensitivity. To determine the potential role of radiosensitivity in predisposition of prostate cancer by comparing lymphocyte radiosensitivity of prostate cancer patients with healthy donors. In this experimental study, the blood samples of 10 prostate cancer patients and 10 healthy donors were irradiated to 0.25, 0.5, 1, 2, 4 and 6 Gy ionizing radiation produced by a 6MV Linac. One sample of each group receiving no radiation was regarded as the background. The micronuclei (MN) and chemical premature chromosome condensation (PCC) cytogenetic tests were performed on all samples and the numbers of MN and PCC rings were scored. Dose-response curves were plotted for both healthy and cancerous groups with two tests. There was a significant difference between the numbers of MN within each group due to different levels of radiation doses. There was also a significant difference between the two groups in all identical doses, with the exception of 6 Gy. The chemical PCC test indicated a significant difference between the scored PCC rings in each group at doses higher than 0.25 Gy. However, no differences were noted between the healthy donors and prostate cancer patients receiving the same level of doses. MN test can be considered as a reliable indicator of predisposition of prostate cancer. On the other hand, the chemical PCC test could not differentiate between healthy donors and prostate cancer patients at the dose range examined in this study.
Sections du résumé
BACKGROUND
BACKGROUND
Cytogenetic tests are usually used for diagnosing predisposed individuals to cancer by determining their lymphocyte radiosensitivity.
OBJECTIVE
OBJECTIVE
To determine the potential role of radiosensitivity in predisposition of prostate cancer by comparing lymphocyte radiosensitivity of prostate cancer patients with healthy donors.
MATERIALS AND METHODS
METHODS
In this experimental study, the blood samples of 10 prostate cancer patients and 10 healthy donors were irradiated to 0.25, 0.5, 1, 2, 4 and 6 Gy ionizing radiation produced by a 6MV Linac. One sample of each group receiving no radiation was regarded as the background. The micronuclei (MN) and chemical premature chromosome condensation (PCC) cytogenetic tests were performed on all samples and the numbers of MN and PCC rings were scored. Dose-response curves were plotted for both healthy and cancerous groups with two tests.
RESULTS
RESULTS
There was a significant difference between the numbers of MN within each group due to different levels of radiation doses. There was also a significant difference between the two groups in all identical doses, with the exception of 6 Gy. The chemical PCC test indicated a significant difference between the scored PCC rings in each group at doses higher than 0.25 Gy. However, no differences were noted between the healthy donors and prostate cancer patients receiving the same level of doses.
CONCLUSION
CONCLUSIONS
MN test can be considered as a reliable indicator of predisposition of prostate cancer. On the other hand, the chemical PCC test could not differentiate between healthy donors and prostate cancer patients at the dose range examined in this study.
Identifiants
pubmed: 32802789
doi: 10.31661/JBPE.V0I0.657
pii: JBPE-10-4
pmc: PMC7416091
doi:
Types de publication
Journal Article
Langues
eng
Pagination
411-420Informations de copyright
Copyright: © Journal of Biomedical Physics and Engineering.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
Mutat Res Genet Toxicol Environ Mutagen. 2014 Oct;773:23-8
pubmed: 25308702
Int J Radiat Biol. 1994 Nov;66(5):427-32
pubmed: 7983426
Rep Pract Oncol Radiother. 2011 Oct 29;17(1):24-31
pubmed: 24376993
Radiat Res. 2010 Jan;173(1):71-8
pubmed: 20041761
Cancer Res. 1998 Sep 15;58(18):4117-21
pubmed: 9751622
Br J Cancer. 2002 Dec 2;87(12):1379-85
pubmed: 12454765
Cancer Res. 2000 Jan 15;60(2):390-4
pubmed: 10667592
Lancet. 1994 Nov 19;344(8934):1444
pubmed: 7968110
Cancer Genet Cytogenet. 1995 Feb;79(2):133-5
pubmed: 7889505
Cytogenet Genome Res. 2004;104(1-4):365-70
pubmed: 15162066
Mutagenesis. 2006 Sep;21(5):313-20
pubmed: 16928695
Health Phys. 2015 Mar;108(3):371-6
pubmed: 25627950
Int J Radiat Biol. 2002 May;78(5):341-6
pubmed: 12020425
Cancer Lett. 2007 Nov 18;257(2):263-73
pubmed: 17881118
Carcinogenesis. 2008 Jun;29(6):1178-83
pubmed: 18356148
Cancer Res. 2000 Mar 15;60(6):1619-25
pubmed: 10749131
Cancer Res. 1994 Jun 1;54(11):2919-22
pubmed: 8187078
Mutat Res. 2015 Jul;777:52-9
pubmed: 25942615
Radiat Environ Biophys. 2016 Mar;55(1):41-51
pubmed: 26507139
Mutat Res. 2001 Apr 5;491(1-2):9-16
pubmed: 11287292
Radiother Oncol. 2010 Jul;96(1):19-24
pubmed: 20452694
Mutat Res Genet Toxicol Environ Mutagen. 2015 Nov;793:107-14
pubmed: 26520380
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1245-52
pubmed: 17145539
Radiother Oncol. 2006 Dec;81(3):257-63
pubmed: 17113667
Radiother Oncol. 2011 Oct;101(1):28-34
pubmed: 22014898
Int J Radiat Biol. 1999 Jan;75(1):1-10
pubmed: 9972785
Int J Radiat Biol. 1998 Oct;74(4):457-62
pubmed: 9798956
Br J Cancer. 1998 Feb;77(4):614-20
pubmed: 9484819
Exp Oncol. 2012 Jul;34(2):121-4
pubmed: 23013765
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):640-9
pubmed: 25596111
Int J Radiat Biol. 1997 Dec;72(6):693-701
pubmed: 9416792
J Radiat Res. 2005 Mar;46(1):111-6
pubmed: 15802866
Ann ICRP. 2016 Jun;45(1 Suppl):290-6
pubmed: 27012844
ScientificWorldJournal. 2006 Sep 25;6:1174-90
pubmed: 17013523
Br J Cancer. 2001 Apr 6;84(7):892-6
pubmed: 11286467
Nat Protoc. 2007;2(5):1084-104
pubmed: 17546000
Carcinogenesis. 2002 May;23(5):687-96
pubmed: 12016139